The Molecular Virology Basic Research Program (MVBRP) is an interdisciplinary basic research Program consisting of 17 independent but interactive laboratories with common interests in the molecular biology and immunology of viruses relevant to cancer and related topics. The overall goal of this Program is to facilitate research into the basic mechanisms of viral tumorigenesis and viral immunology;to conduct investigations that may lead to novel approaches to prevent or treat tumors associated with viruses;or to use viruses themselves as vaccines or oncolytic agents. Under the leadership of Daniel DiMaio, M.D., Ph.D., a tumor virologist who focuses on papillomaviruses, the MVBRP accomplishes these goals primarily by sponsoring the Molecular Virology and Oncology Group Meetings and the Steven Degar Memorial Lectureship, by encouraging and stimulating collaborative research, and by providing access to YCC funds and shared resources. Dr. DiMaio, along with other Program faculty, directs the graduate level course, The Molecular Biology of Animal Viruses. He is also the Principal Investigator of the NCI-funded Program Project Grant, Molecular Basis of Viral and Cellular Transformation, as well as an NCI-funded postdoctoral training grant in tumor virology and an NIAID-funded predoctoral training grant in virology. The distinguished faculty of this Program includes members of the National Academy of Sciences (Steitz) and the Institute of Medicine (Miller and Steitz). In aggregate, the Program members have received seven NIH MERIT Awards. There are now substantial efforts in the areas of basic tumor virology, vaccine development and viral immunology, and oncolytic viruses. In the last grant period, members of this Program published 243 cancer related papers, of which 4.1% were intra-programmatic and 18% inter-programmatic. Because viruses play a causal role in a substantial fraction of human tumors, studies carried out in this Program may eventually have an important impact on cancer prevention and treatment by revealing the mechanisms responsible for viral replication and tumorigenesis, thus identifying novel targets for translational efforts. In addition, these studies will reveal the mechanistic basis of biological phenomena that are relevant to the development and treatment of many cancers, including those not associated with viruses. The Molecular Virology Program currently has 18 members from 12 departments, with total research funding of $7.2 million direct costs ($10.6 million total costs), of which $6.3 million direct costs is peer-reviewed and $2.7 million direct costs is NCI-funded.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-32
Application #
8132521
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
32
Fiscal Year
2010
Total Cost
$33,424
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications